Conference Day One | Wednesday, October 16

7:50 am Check In & Morning Coffee

8:50 am Chair’s Opening Remarks

Evaluating the Current Clinical Success & Looking Toward the Future in TGF-β Targeted Therapies

9:00 am The Accomplishments of TGF-β Directed Therapies in Immuno-Oncology

  • Tony Reid Chief Executive Officer, EpicentRx


  • Navigating from preclinical to clinical trials in immuno-oncology to maintain positive patient response
  • Unearthing clinical efficacy and activity of TGF-β targeted therapy to celebrate success
  • Discovering the next steps in the TGF-β space for clinical triumph

New Data!

9:30 am Fireside Chat: Assessing the TGF-β Landscape & Predicting Future Innovations


  • Exploring the current clinical successes of TGF-β targeted therapies
  • Discussing the changes in the TGF-β field with the pivot to fibrosis research
  • Looking to the future for developing TGF-β directed therapies and exciting new technologies using TGF-β

10:30 am Morning Break & Speed Networking


This networking session is your opportunity to get face-to-face with many of the brightest minds working in the TGF-β field and establish meaningful business relationships to pursue for the rest of the conference.

Utilizing Combination Therapies to Enhance the Function of TGF-β Targeted Therapies

11:30 am Promoting Inflammation to Turn Tumors From ‘Cold’ to ‘Hot’ By Uniting TGF-β Directed Drugs & Checkpoint Inhibitors for More Effective Treatments


  • Exploiting the immune system by combining TGF-β targets and checkpoint inhibitors to see positive patient response
  • Heating the tumor up by encouraging inflammation for a strong immune response to therapy
  • Overcoming immunotherapy resistance with TGF-β targeted therapy and checkpoint inhibitors to achieve clinical success

12:00 pm Utilizing Combination Therapies Targeting Diverse TGF-β-Dependent Anti- Fibrotic & Immunosuppressive Mechanisms in Oncology


  • Refocusing from mono-directed TGF-β therapies to combination treatments for novel and effective anti-cancer therapies
  • Exploring alternatives to checkpoint inhibitors for novel combination therapies using TGF-β targeted therapies
  • Deep diving into ALK5 inhibitors in conjunction with autotaxin inhibitors to show clinical efficacy

New Data!

12:30 pm Overcoming Challenges of TGF-β Targeted Therapies by Selecting Suitable Combinations to Achieve Clinical Success


  • Investigating different potential checkpoint inhibitors (SMAD, PD1) with TGF-β targetedtherapies for the most effective patient response
  • Advancing to the next level by using proven combination TGF-β directed therapies to show clinical efficacy
  • Employing a multi-pronged method to turn tumors from cold to hot

1:00 pm Networking Lunch

Unearthing Cutting-Edge Biomarkers & Monitoring the Patient Response to TGF-β Directed Therapies for Improved Patient Selection

2:00 pm Discovering New & Predictive Biomarkers for TGF-β to Improve Patient Predictive Response to Targeted Therapies

  • Vaishali Shinde Senior Director - Translational & Clinical Assay Lead, Corbus Pharmaceuticals


  • Uncovering biomarkers for TGF-β targeted therapies to improve patient selection
  • Finding TGF-β unique biomarkers that prove clinical viability
  • Recognizing patient response by following TGF-β biomarkers to determine the most effective treatments

2:30 pm Roundtable Discussion: Examining the Patient Response During Trials to Prove the Clinical Benefit & Improve Patient Selection

  • Jack Chen Scientific Director - IO Translational Research Group Lead, Precision Medicine, Abbvie
  • Anthony Maida Chief Clinical Officer - Translational Medicine, Oncotelic Therapeutics


  • Scrutinizing patient response throughout treatment by following TGF-β biomarkers to improve later clinical selection
  • Assessing the tumor microenvironment pre- and post-TGF-β targeted therapies to prove clinical efficacy
  • Employing biomarkers to find clinical efficacy of TGF-β directed therapies

3:00 pm Afternoon Networking Break

Unlocking the Next Wave of TGF-β Directed Therapies Beyond Immuno-Oncology Towards Clinical Success

3:30 pm Investigating the Impact of Systemic & Targeted TGF-β Blockade on Fibrosis and Inflammation


  • Comparing systemic TGF-β R1 inhibition to restricted targeting
  • Uncovering the unique effects on inflammation observed in fibrotic models
  • Highlighting lessons learned for fibrosis therapeutics and beyond

New Data!

4:00 pm Showcasing CUE-401: A Novel TGF-β/ IL-2 Fusion Protein for the Induction & Expansion of FOXP3+ Regulatory T Cells


  • Exploring TGF-β and IL-2 as two key signals for the induction of regulatory T cell populations
  • Developing CUE-401 as a novel TGF-β and IL-2 directed therapy for the selective expansion of regulatory T cells in vivo
  • Unearthing the mechanism of action and the activity of CUE-401

New Data!

4:30 pm Spotlighting Immunotherapy for Autoimmune Diseases by Cell-Targeted Nanoparticles that Induce Local Production of TGF-β


  • Discussing the mechanism of action of therapeutic nanoparticles that can generate TGF-β locally
  • Determining the variety of disease indications for these cell-targeted nanoparticles
  • Avoiding the possible toxicity of encapsulated TGF-β in nanoparticles by local generation of TGF-β

5:00 pm Chairs Closing Remarks

5:15 pm End of Conference Day One